佟仲生

佟仲生，男，医学硕士。主任医师，硕士生导师。现就职于天津市肿瘤医院乳腺肿瘤内科，任天津市肿瘤医院乳腺肿瘤内科主任。

专业特长：

从事肿瘤专业化疗临床与基础研究工作多年，具有丰富肿瘤学专业造诣及临床实践经验，作为乳腺肿瘤内科治疗的学科带头人，尤精于乳腺癌综合治疗。对乳腺癌的新辅助、辅助及晚期乳腺癌的化学治疗有较深造诣。

教育执业经历：

1986年毕业于天津医科大学医学系获学士学位，天津医科大学肿瘤学硕士。

2004-2005年作为访问学者在美国密西根大学基础与临床工作。

科研与论著：

主持多项抗癌新药的Ⅰ、Ⅱ、Ⅲ期临床研究，参与国际多中心临床研究工作40余项，目前承担多项国家、市级重大专项等课题研究，率先开展局部晚期乳腺癌光动力治疗的基础与临床研究，开辟了光动力转化医学研究新领域，并获2014年度天津科技进步三等奖。多次受邀参加国内外学术会议大会发言。

国内外发表论文80余篇，主编论著1部。参与完成论著7部。

学术任职：

中国抗癌协会靶向治疗专业委员会常委、天津市抗癌协会临床化疗专业委员会主任委员、天津市医药学专家协会肿瘤专业委员会主任委员、中国乳腺癌专业委员会委员、天津医学会肿瘤学分会委员。

《中国肿瘤临床》杂志编委、《天津医药》编委、《中国综合临床》编委。

主要论文：

Ge J, Yu Y, Xin F, Yang ZJ, Zhao HM, Wang X, Tong ZS, Cao XC. Downregulation of delta-aminolevulinate dehydratase is associated with poor prognosis in patients with breast cancer.Cancer Sci. 2017 Feb 3.[Epub ahead of print]

Wang S, Li W, Wang F, Niu Y, Hao C, Wang X, He L, Tong Z. 36 cases adenoid cystic carcinoma of the breast in China: Comparison with matched grade one invasive ductal carcinoma-not otherwise specified. Pathol Res Pract. 2017 Apr;213(4):310-315.

Zhang P, Sun T, Zhang Q, Yuan Z, Jiang Z, Wang XJ, Cui S, Teng Y, Hu XC, Yang J, Pan H, Tong Z, Li H, Yao Q, Wang Y, Yin Y, Sun P, Zheng H, Cheng J, Lu J, Zhang B, Geng C, Liu J, Peng R, Yan M, Zhang S, Huang J, Tang L, Qiu R, Xu B; BG01-1323L study group. Utidelone plus capecitabine versus capecitabine alone for heavily pretreated metastatic breast cancer refractory to anthracyclines and taxanes: a multicentre, open-label, superiority, phase 3, randomised controlled trial. Lancet Oncol. 2017 Mar;18(3):371-383.

Zhang L, Wu Y, Liu F, Fu L, Tong Z. Characteristics and survival of patients with metachronous or synchronous double primary malignancies: breast and thyroid cancer. Oncotarget. 2016 Aug 9;7(32):52450-52459.

Shi YH, Dai DF, Li J, Dong YW, Jiang Y, Li HG, Gao Y, Chong CK, Li HY, Chu XQ, Yang C, Zhang Q, Tong ZS, Bai CG, Chen Y. Sulforaphane Analogues with Heterocyclic Moieties: Syntheses and Inhibitory Activities against Cancer Cell Lines. Molecules. 2016 Apr 21;21(4):514.

Zhang P, Tong Z, Tian F, Wang Y, Yang J, Li W, Di L, Liu W, Tang L, Qiu R, Xu B. Phase II trial of utidelone as monotherapy or in combination with capecitabine in heavily pretreated metastatic breast cancer patients. J Hematol Oncol. 2016 Aug 11;9(1):68.

Zhang Q, Shao Z, Shen K, Li L, Feng J, Tong Z, Gu K, Wang X, Xu B, Sun G, Chen H, Rukazenkov Y, Jiang Z.Fulvestrant 500 mg vs 250 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer: a randomized, double-blind registrational trial in China. Oncotarget. 2016 Aug 30;7(35):57301-57309.

Yang M, Liu F, Higuchi K, Sawashita J, Fu X, Zhang L, Zhang L, Fu L, Tong Z, Higuchi K. Serum amyloid A expression in the breast cancer tissue is associated with poor prognosis. Oncotarget. 2016 Jun 14;7(24):35843-35852.

Xu B, Tian F, Yu J, Song Y, Shi J, Zhang B, Zhang Y, Yuan Z, Wu Q, Zhang Q, Nan K, Sun Q, Li W, Hu J, Bi J, Meng C, Dai H, Jiang H, Yue S, Cao B, Sun Y, Wang S, Tong Z, Shen P, Wu G, Tang L, Deng Y, Jia L, Shen K, Zhuang W, Xie X, Wu Y, Chen L. A multicenter, randomized, controlled, phase Ⅲ clinical study of PEG-rhG-CSF for preventing chemotherapy-induced neutropenia in patients with breast cancer and non-small cell lung cancer. Zhonghua Zhong Liu Za Zhi. 2016 Jan;38(1):23-7.

Zhao W, Wang J, Zhu B, Duan Y, Chen F, Nian W, Sun J, Zhang B, Tong Z, Chen Z. IGFBP7 functions as a potential lymphangiogenesis inducer in non-small cell lung carcinoma. Oncol Rep. 2016 Mar;35(3):1483-92.

Jia Y, Zhou L, Tian C, Shi Y, Wang C, Tong Z. Dynamin-related protein 1 is involved in micheliolide-induced breast cancer cell death. Onco Targets Ther. 2015 Nov 16;8:3371-81.

Wang C, Ju H, Shen C, Tong Z. miR-429 mediates δ-tocotrienol-induced apoptosis in triple-negative breast cancer cells by targeting XIAP. Int J Clin Exp Med. 2015 Sep 15;8(9):15648-56.

Jia Y, Zhou L, Tian C, Shi Y, Wang C, Tong Z. Dynamin-related protein 1 is involved in micheliolide-induced breast cancer cell death. Onco Targets Ther. 2015 Nov 16;8:3371-81.

Lu N, Tong Z, Zhang M, Lu L, Cao H. Effect and mechanism of EGFR expression in macrophages on the anti-cancer effect of berberine on colorectal cancer. Zhonghua Zhong Liu Za Zhi. 2015 May;37(5):342-6.

Yuan P, Di LJ, Liu W, Wan DG, Dai H, Tong ZS, Du F, Xu BH. Phase II multi-center clinical study on using S-1 to treat advanced breast cancer after resistance to anthracycline and taxane drugs in Chinese patients. Int J Clin Exp Med. 2015 Feb 15;8(2):3072-9.

Xu B, Hu X, Jiang Z, Li H, Chen J, Cui S, Li Q, Liao N, Liu D, Liu J, Lu J, Shen K, Sun T, Teng Y, Tong Z, Wang S, Wang X, Wang X, Wang Y, Wu J, Yuan P, Zhang P, Zhang Q, Zheng H, Pang D, Ren G, Shao Z, Shen Z, Song E, Song S. National consensus in China on diagnosis and treatment of patients with advanced breast cancer. Ann Transl Med. 2015 Oct;3(17):242.

Jia Y, Zhang C, Zhou L, Xu H, Shi Y, Tong Z. Micheliolide overcomes KLF4-mediated cisplatin resistance in breast cancer cells by downregulating glutathione. Onco Targets Ther. 2015 Aug 28;8:2319-27.

Dong G, Jia Y, Wang X, Li S, Wang C, Shi Y, Tong Z. The comparison of maintenance treatment with capecitabine (CMT) and non-maintenance treatment with capecitabine (non-CMT) in patients with metastatic breast cancer. Int J Clin Exp Med. 2015 May 15;8(5):8283-7. 

出诊时间：周一上午（具体以当天公示为准）

扫描上面二维码在移动端打开阅读